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ABSTRACT
We report the case of a 19-year-old female with cere-
bellar ganglioglioma that was diagnosed at 4 years of 
age. Despite treatment with partial resection, radiation, 
and chemotherapy, residual tumor slowly expanded into 
the brainstem and upper cervical cord, resulting in noc-
turnal hypopnea, progressive tetraparesis, and feeding 
difficulty during 8–10 years of age. Initiation of temo-
zolomide and bevacizumab was effective in preventing 
further expansion of the tumor, and the patient has been 
treated at home and in school with noninvasive positive 
pressure ventilation and gastrostomy. Histopathologic 
examination of the resected tumor tissue revealed phos-
pho-S6-positive tumor cells of either neuronal or astrog-
lial appearance. This suggests that a higher proportion 
of cells of glial lineage could be linked to the progres-
sion of cerebellar ganglioglioma in childhood. Possible 
treatment options with mammalian target of rapamycin 
inhibitors are discussed.
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Gangliocytoma (GC) and ganglioglioma (GG) are 
generally benign brain tumors, with a long-term recur-
rence-free survival rate of > 90%. The distinction be-
tween GC and GG is based on the absence or presence 
of glial tumor cell elements. Location in the temporal 
lobe, longstanding epilepsy, and complete surgical re-
section are associated with a good prognosis in GG.1 
Adult-onset dysplastic cerebellar GC, which is synon-
ymous with Lhermitte–Duclos disease (LDD), is char-
acterized by a lack of progression in most cases.2 In the 
absence of these particularly favorable conditions, the 
prognosis of cerebellar GG in childhood may be vari-
able. Here we describe a case of cerebellar GG in child-
hood, which emphasizes the quality of life in patients 
with long-term survival along with moderate-to-severe 
neurological impairment.
 Mutations in the phosphatase and tensin homolog 
(PTEN) gene with resulting activation of the mamma-
lian target of rapamycin (mTOR) pathway are common 
in adult LDD but are not established in childhood GC or 
GG.2 We conducted histopathologic examination of the 
surgical specimen from the patient to obtain the basis for 
a possible treatment option with mTOR inhibitors.
PATIENT REPORT
The patient was born and normally developed until 3 
years of age, when she manifested with right torticol-
lis, drooped right corner of the mouth, and excessive 
drooling for her age. Intention tremor, dysdiadochoki-
nesis, scanning speech, and nystagmus were noted on 
examination at 6 years of age. Magnetic resonance 
imaging (MRI) revealed a tumor in the right cerebellar 
hemisphere, intruding into the vermis, brainstem, and 
upper cervical cord (Figs. 1A and E). Histopathologic 
examination of the partially resected tumor revealed 
a mixture of ganglion-like and less prominent astrog-
lia-like cells, which was consistent with a diagnosis of 
GG (Figs. 2A and B). Despite postoperative radiation 
therapy of 44 Gy, the tumor mass slowly expanded (Figs. 
1B and F). The patient developed a wide-based gait with 
repeated falls, dysarthria, left-sided hearing loss, and 
frequent sleep apnea at 8 years of age, resulting in the 
use of a wheelchair at 9 years of age and nighttime non-
invasive positive pressure ventilation (NPPV) and gas-
trostomy at 10 years of age. Temozolomide 200 mg/m2/
day for 5 days every 4 weeks was initiated at 12 years 
of age, which prevented further expansion of the tumor 
(Figs. 1C and G). However, swelling of the infiltrated 
upper cervical cord developed at 17 years of age (Fig.1D 
256
K. Ohno et al.
and H). An additional administration of bevacizumab 
10 mg/kg every 2 weeks resulted in amelioration of the 
edema and cavitation in the cervical cord. The patient 
has required recurrent hospital admission for bronchial 
asthma once or twice per year since the age of 12 years. 
She is currently 19 years old (height, 153 cm; weight, 
38 kg). She has spastic tetraparesis with right-sided pre-
dominance and left facial paraplegia. Dysmetria in the 
left hand is also noted. She can stand up slowly from the 
supine position and walk by holding on to objects. Pha-
ryngeal reflex is depressed, and tongue fasciculation is 
present. Her intelligence quotient at 15 years of age was 
assessed to be 51 (verbal, 56; performance, 55) using the 
Wechsler Intelligence Scale for Children (4th edition). 
She graduated from a high school for disabled children 
and is now living with her family and participating in 
activities at local day-care centers.
 Since the patient was 17 years old, we performed 
immunohistochemical investigation of the paraffin-em-
bedded surgical specimen, with the hope of finding a 
basis for further treatment options. Surgical specimen 
was taken from the left posterior cerebellar hemisphere 
(see the square-shaped tissue defect at the left posteri-
or cerebellum in the bottom image in Figs. 1B and C). 
Four-mm-thick sections were immersed in 3% hydrogen 
peroxide for 5 min to abolish endogenous peroxidase 
activity. The sections were incubated with the primary 
antibody against synaptophysin (mouse monoclonal, di-
Figure 1 
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Fig. 1. Evolution of the infratentorial tumor on magnetic resonance imaging at the age of 6 years (A, E), 12 years (B, F), 13 years (C, G), 
and 18 years (D, H). A–D, G, and H: T2-weighted imaging; E and F: gadolinium-enhanced T1-weighted imaging.
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Fig. 2. Histopathologic finding of the cerebel-
lar tumor surgically resected at 6 years of age. 
A and B: Hematoxylin–Eosin (HE) staining; 
and immunostaining of C: synaptophysin, D: 
glial fibrillary acidic protein, E and F: phos-
phorylated S6, G: phosphatase and tensin ho-
mologue deleted on chromosome 10 (PTEN); 
counterstained with HE, H: phosphorylated 
PTEN. A, F, I–K, Bar = 50 µm; B–D, G, Bar 
= 25 µm; E and H, Bar = 100 µm. 
A and B: Tumor tissue is composed of gangli-
on-like large cells with large transparent nuclei 
and eosinophilic soma, and astroglia-like 
small cells with dark small nuclei. These are 
compatible with the diagnosis of ganglioglio-
ma [2]. Ganglion were immunopositive for synaptophysin (C, arrows), and astroglia-like cells are immunopositive for glial fibrillary acid-
ic protein (D, arrows). E: Ganglion-like tumor cells (arrows) infiltrating from cerebellar white matter (right side) into the granular layer (left 
side), immunopositive for phosphorylated S6. F: Ganglion-like (thick arrows) and astroglia-like cells (thin arrows) replacing the cerebellar 
white matter, both immunopositive for phosphorylated S6. G: PTEN-positive ganglion-like tumor cells in the cerebellar white matter 
and granular layer (thick arrows). Note that the Purkinje cells (thin arrows) and granule cells are immunonegative for PTEN. H: Rare 
ganglion-like cells (arrow) are immunopositive for phosphorylated (inactivated) PTEN. I–K: Immunostaining in the deep white matter 
of the surgically resected specimen. I: Rare ovoid-shaped cells (arrows) are immunopositive for Ki-67. J: No cells are immunopositive for 
MGMT. Intravascular erythrocytes are falsely positive, presumably due to residual internal peroxidase activity (arrows). K: Many astrog-
lia-like cells are immunostained with anti-P-S6 antibody (rabbit polyclonal, diluted at 1:200; Cell Signaling Technology, Danvers, MA). 
Bar = 50 µm.
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luted at 1:100; Boehringer-Mannheim, Indianapolis, IN), 
glial fibrillary acidic protein (mouse monoclonal, ready-
to-use; BioGenex, San Ramon, CA), phosphorylated S6 
ribosomal protein (P-S6) (rabbit polyclonal, diluted at 
1:200; Cell Signaling Technology, Danvers, MA), PTEN 
(mouse monoclonal, diluted at 1:100; Santa Cruz, Dallas, 
TX), phosphorylated-PTEN (rabbit monoclonal, Ori-
Gene, Rockville, MD), Ki-67 (mouse monoclonal, ready 
to use, Clone MIB-1, DAKO, CA), or O6-methulgua-
nine-DNA-methyltransferase (MGMT) (mouse mono-
clonal, ready to use, abcam, Cambridge, UK) overnight 
at 4 ºC. The appropriate Vectastain Avidin-biotin-immu-
noperoxidase complex (ABC) kits (Vector Laboratories, 
Burlingame, CA) were used to detect bound the antibod-
ies mentioned above. 3,3’-diaminobenzidine tetrahydro-
chloride (DAB) was the final chromogen. Between each 
step, the sections were thoroughly washed with phos-
phate-buffered saline 3 times.
 As expected, the ganglion cell-like tumor cells were 
positive for synaptophysin (Fig. 2C), and the astrog-
lia-like tumor cells were positive for glial fibrillary acid-
ic protein (Fig. 2D). In addition, the ganglion cell-like 
and astroglia-like tumor cells were both immunopositive 
for P-S6, a downstream product of PTEN/mTOR path-
way (Figs. 2E, F and K). In addition, most ganglionic 
cells were immunopositive for PTEN (Fig. 2G), and a 
small proportion of ganglionic cells were immunopos-
itive for phosphorylated-PTEN (Fig. 2H). MIB-1 index 
was < 1% (Fig. 2I), and MGMT immunostaining was 
absent (Fig. 2J) in the surgical specimen.
DISCUSSION
Because the proportion of astroglia-like tumor cells was 
small in the surgical specimen, we were not confident 
that either GC or GG was the most appropriate patholog-
ic diagnosis for the patient. However, the extension of the 
tumor into the brainstem and spinal cord and absence of 
the typical findings of GC in LDD, including the striated 
pattern in the cerebellar cortex on MRI and the thick-
ened granular cell layer on histopathologic examination, 
were suggestive of a less favorable outcome. Progressive 
neurological impairment could be terminated only after 
initiation of combination therapy with temozolomide and 
bevacizumab, which is usually employed for treatment 
of anaplastic GG.3 Malignant transformation of GG 
preferentially occurs within the glial component.4 Evo-
lution of a LDD-like tumor to GG, and subsequently to 
anaplastic GG,5 is consistent with this trend and suggests 
that glial proliferation can become obvious later in the 
course in childhood GC-like lesions. In the present case, 
mTOR activation in both the ganglion-like and astrog-
lia-like cells on initial pathologic evaluation may further 
support the primary gliomatous origin of glial cells and 
the diagnosis of GG. Retrospectively, the surgical spec-
imen of tumor may have not reached the deep, possibly 
more malignant portion involving the brainstem (Figs. 
1A and B). A second biopsy from the deep structure for 
assessment of MIB-1 index and MGMT immunostain-
ing, along with genetic analysis of CDKN2 deletion and 
BRAF V6000E mutation, might have revealed evidence 
of anaplastic transformation.7, 8 However, we decided 
not to conduct the second biopsy before initiation of te-
mozolomide and bevacizumab, considering the risk of 
surgical intervention at the advanced stage of illness.
 In LDD, increased P-S6 immunoreactivity in GC 
tumor cells represents mTOR activation due to disrup-
tion of PTEN activity.2, 6 However, PTEN expression 
was preserved and no PTEN mutation was detected in 
childhood cerebellar GC, in contrast to adult GC with 
LDD.2, 6 This suggests that the pathological mechanism 
of childhood cerebellar GC is distinct from that in adult 
LDD. As in LDD, the mTOR pathway is activated in 
GG,9, 10 as well as in low- or high-grade gliomas, in 
childhood.11 PTEN gene methylation (inactivation) due 
to an unknown mechanism, accompanied by activation 
of the mTOR pathway, is linked to lower survival in 
cases of glioma.11, 12 It remains to be elucidated wheth-
er mTOR activation and increased P-S6 expression in 
childhood GC or GG are caused by augmented PTEN 
methylation. The preserved PTEN immunoreactivity 
in our case suggests that childhood GG shares certain 
pathological mechanisms with childhood GC.2 Interest-
ingly, the mTOR inhibitor sirolimus was effective for re-
fractory childhood ependymoma with augmented P-S6 
expression proven by immunohistochemistry.13 Thus, 
mTOR inhibitors may be worth a trial in childhood glio-
mas and GG, particularly with findings of mTOR activa-
tion in the tumor tissue.
 Childhood cerebellar GC or GG can have a slowly 
progressive course, as in the present patient. Treatment 
strategies and physico-social aids may need to be specifi-
cally planned in individual patients; atypical findings for 
LDD on neuroimaging, proliferation of glial components, 
and activation of the mTOR pathway on histopathologic 
examination of the surgical specimen may indicate a 
risk of progressive disease. We may need to be prepared 
for possible treatment options, including temozolomide, 
bevacizumab, and mTOR inhibitors. These regimens 
require only oral administration or short-term admission, 
thereby permitting outpatient treatment. To obtain a bet-
ter quality of life in patients with long-term survival with 
moderate-to-severe neurological impairment, NPPV and 
gastrostomy could be helpful for children with cerebellar 
GC or GG and brainstem involvement.
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